期刊
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
卷 91, 期 4, 页码 1305-1308出版社
ENDOCRINE SOC
DOI: 10.1210/jc.2005-2507
关键词
-
资金
- NCI NIH HHS [P50 CA 90381] Funding Source: Medline
- NCRR NIH HHS [M01 RR 01066] Funding Source: Medline
Context: GnRH agonists markedly increase fat mass in men with prostate cancer, but little is known about the effects of treatment on insulin sensitivity. Objective: The objective of the study was to assess the effects of short-term GnRH agonist treatment on insulin sensitivity. Design: This was a prospective 12-wk study. Setting: The study was conducted at a general clinical research center. Patients or Other Participants: We studied 25 men with locally advanced or recurrent prostate cancer, no radiographic evidence of metastases, no history of diabetes mellitus, and no evidence of diabetes mellitus at baseline visit. Intervention: Leuprolide depot and bicalutamide were used in the study. Main Outcome Measures: Oral glucose tolerance tests and body composition assessment by dual-energy x-ray absorptiometry were performed at baseline and wk 12. The primary study outcome was change in insulin sensitivity index. Results: Mean (+/- SE) percentage fat body mass increased by 4.3 +/- 1.3% from baseline to wk 12 (P = 0.002). Insulin sensitivity index decreased by 12.9 +/- 7.6% (P = 0.02). Insulin sensitivity by homeostatic model assessment decreased by 12.8 +/- 5.9% (P = 0.02). Fasting plasma insulin levels increased by 25.9 +/- 9.3% (P = 0.04). Mean glycosylated hemoglobin also increased significantly (P < 0.001). Conclusions: Short-term treatment with leuprolide and bicalutamide significantly increased fat mass and decreased insulin sensitivity in men with prostate cancer. These observations suggest that GnRH agonists may increase the risk of diabetes mellitus and cardiovascular disease in older men.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据